You can buy or sell Exelixis and other stocks, options, ETFs, and crypto commission-free!
Exelixis, Inc. Common Stock, also called Exelixis, is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. Read More It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA.
Parkway Alameda, California
52 Week High
52 Week Low
Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'
Morgan Stanley has dropped its bearish stance on Exelixis, Inc. (NASDAQ: EXEL), although the research firm hasn't gained enough confidence to recommend buying the drugmaker's stock. The Analyst Scroll to continue with content Ad Analyst Jeffrey Hung upgraded Exelixis from Underweight to Equal-weight and increased the price target from $20 to $28. The Thesis Merck & Co., Inc. (NYSE: MRK)'s Keytruda in combination with Pfizer Inc.(NYSE: PFE)'s Inlyta was recently found to be effective in treating first-l...
Signal Says Buy Options Insurance on This Biotech
Exelixis, Inc. (NASDAQ:EXEL) shares are fresh off a new high, thanks to some upbeat analyst attention. Specifically, Morgan Stanley upgraded the biotech stock to "equal weight" from "underweight," and hiked its price target to $28 from $20, citing strong prescription trends among other reasons. However, if recent history is any indicator, EXEL bulls may want to consider buying options insurance to guard against a short-term pullback. EXEL stock surged as high as $25.31 this morning, representing a new annu...
Yahoo FinanceMar 14
Exelixis (EXEL) Gains As Market Dips: What You Should Know
Exelixis (EXEL) closed the most recent trading day at $24.76, moving +0.2% from the previous trading session. This change outpaced the S&P 500's 0.09% loss on the day. Meanwhile, the Dow gained 0.03%, and the Nasdaq, a tech-heavy index, lost 0.16%. Heading into today, shares of the drug developer had gained 12.06% over the past month, outpacing the Medical sector's gain of 2.75% and the S&P 500's gain of 2.35% in that time. Wall Street will be looking for positivity from EXEL as it approaches its next ear...
Expected May 1, After Hours